LifeMD (NASDAQ:LFMD) Raised to Outperform at Mizuho

Key Points

• Mizuho upgraded LifeMD from "neutral" to "outperform" and raised its price target to $8 (from $6), implying roughly a 101% upside from the current share price.
• LifeMD reported quarterly EPS of ($0.04), missing estimates and generating $46.87M in revenue versus $48.57M expected; the stock trades around $3.98 with a market cap near $191M and a consensus rating of "Moderate Buy" with an average target of $9.14.

LifeMD (NASDAQ:LFMD - Get Free Report) was upgraded by Mizuho from a "neutral" rating to an "outperform" rating in a research note issued on Monday,Benzinga reports. The firm currently has a $8.00 price objective on the stock, up from their prior price objective of $6.00. Mizuho's target price suggests a potential upside of 101.01% from the stock's current price.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded LifeMD from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright upped their target price on shares of LifeMD from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, March 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of LifeMD in a research note on Tuesday, March 10th. KeyCorp dropped their target price on LifeMD from $12.00 to $8.00 and set an "overweight" rating on the stock in a report on Wednesday, November 19th. Finally, Zacks Research raised LifeMD from a "strong sell" rating to a "hold" rating in a research report on Friday, December 19th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.14.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.98 on Monday. LifeMD has a one year low of $2.56 and a one year high of $15.84. The firm has a market capitalization of $190.92 million, a price-to-earnings ratio of 15.31 and a beta of 1.92. The business has a 50-day simple moving average of $3.33 and a 200 day simple moving average of $4.51.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The firm had revenue of $46.87 million during the quarter, compared to the consensus estimate of $48.57 million. On average, sell-side analysts expect that LifeMD will post -0.56 EPS for the current year.

Hedge Funds Weigh In On LifeMD

Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock worth $270,000 after acquiring an additional 2,235 shares during the period. Tower Research Capital LLC TRC grew its position in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock valued at $64,000 after acquiring an additional 2,452 shares during the period. SG Americas Securities LLC raised its holdings in shares of LifeMD by 13.8% in the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company's stock worth $86,000 after purchasing an additional 3,061 shares during the period. Invesco Ltd. lifted its stake in LifeMD by 18.8% in the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company's stock valued at $83,000 after purchasing an additional 3,870 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company's stock valued at $730,000 after purchasing an additional 4,281 shares during the last quarter. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company's core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD's service portfolio spans several specialty areas, including men's health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.